Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Builders FirstSource, Inc. - Common Stock
Hibbett, Inc. - Common Stock
QC Holdings Inc
Tempur Sealy International, Inc. Common Stock
Edit Watchlist
Top Indices
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
My Portfolio
Articles published by Iovance Biotherapeutics, Inc.
< Previous
1
2
3
4
Next >
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
November 20, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present at Upcoming Conference
November 12, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates
November 05, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)
October 29, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
October 28, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026
October 27, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
October 26, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma
October 23, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026
October 19, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 16, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
October 01, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
September 29, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
September 18, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present at Upcoming Conferences
September 04, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
August 21, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
August 06, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
July 30, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 17, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
June 19, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
June 03, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
June 01, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
May 22, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present at Upcoming Conference
May 21, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
May 07, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
April 27, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 20, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present at Upcoming Conferences
February 26, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
February 24, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
February 24, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
February 20, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.